Skip to main content
ANIK
NASDAQ Life Sciences

Anika Beats on Revenue Growth, Raises EBITDA Outlook Despite Hyalofast FDA Rejection

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$18.81
Mkt Cap
$258.693M
52W Low
$9.01
52W High
$22.88
52W Position info
109% above low
Off High info
18% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

ANIK has more than doubled off its 52-week low of $9.01.

Summary

Anika posted Q3 2026 revenue of $30.6 million, up 10% year over year, with Commercial Channel revenue up 17% to $14.0 million and OEM Channel up 5% to $16.6 million. Gross margin jumped to 62% from 56%, and adjusted EBITDA came in at $5.1 million versus $0.9 million a year ago. The company raised the low end of its 2026 total revenue growth range to 6%-10% from 5%-10% and lifted 2026 adjusted EBITDA margin guidance to 15%-17% from 13%-17%, though it cut Commercial Channel growth guidance to 9%-13% from 12%-18% on a slower elective surgery market. Two items carry real weight: a new 10-year Hyvisc distribution deal with Boehringer Ingelheim that brings $8 million in total payments including a $4 million upfront in Q1 2027, and an October FDA notice that the Hyalofast PMA application is not approvable on the clinical data submitted. Cash stood at $45.0 million at quarter end. The 2027 revenue outlook of flat to 5% growth is the number to focus on — it implies a sharp deceleration from 2026 and sits alongside the Hyalofast setback.

At the time of this announcement, ANIK was trading at $18.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $258.7M. The 52-week trading range was $9.01 to $22.88. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ANIK - Latest Insights

ANIK
Nov 06, 2026, 2:51 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.62
Real-time Price: $13.23 info
Change: -$1.39 (-10%) info
Market Cap: $177.22M info
ANIK
Nov 06, 2026, 7:06 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $18.81
Real-time Price: $13.23 info
Change: -$5.58 (-30%) info
Market Cap: $177.22M info
ANIK
Jul 29, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.49
Real-time Price: $13.23 info
Change: -$3.26 (-20%) info
Market Cap: $177.22M info
ANIK
Jul 29, 2026, 7:20 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.50
Real-time Price: $13.23 info
Change: -$2.27 (-15%) info
Market Cap: $177.22M info
ANIK
Jun 23, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $14.59
Real-time Price: $13.23 info
Change: -$1.36 (-9%) info
Market Cap: $177.22M info